Syndax reports that the MAXPIRe Phase 2 trial of Axatilimab in Idiopathic Pulmonary Fibrosis did not achieve its primary endpoint.

Observed price moves

• SNDX-14.92%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.